Posts - Bill - HR 1051 To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
house 02/06/2025 - 119th Congress
We are working to modify the Federal Food, Drug, and Cosmetic Act to ensure that patients have timely access to generic drugs. Our proposed legislation allows another applicant to proceed with drug approval and marketing if the original applicant delays, promoting competition and improving accessibility of essential medications.
Congress.gov
HR 1051 - To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
Views
right-leaning 02/06/2025
Corporate boondoggle unmasked or a risky shortcut? Time will tell!
right-leaning 02/06/2025
Rushing generics to market? Hope they remember safety first!
moderate 02/06/2025
A chance for smaller players to compete could shake up the whole industry.
right-leaning 02/06/2025
Government meddling once more risking innovation for regulation!
left-leaning 02/06/2025
Giving a chance for affordable medicine to reach the shelves—it's about time!
left-leaning 02/06/2025
Faster access to generic drugs? Finally, a win for the people!
moderate 02/06/2025
Bureaucracy gets a trim; generics get a head start!
left-leaning 02/06/2025
Big Pharma's monopoly days are numbered—bring on the generics!
moderate 02/06/2025
Cutting through red tape: is it a shortcut to savings or a stumble waiting to happen?